The anti-tumor efficacy of 3C23K, a glyco-engineered humanized anti-MISRII antibody, in an ovarian cancer model is mainly mediated by engagement of immune effector cells

Ovarian cancer is the leading cause of death in women with gynecological cancers and despite recent advances, new and more efficient therapies are crucially needed. Müllerian Inhibiting Substance type II Receptor (MISRII, also named AMHRII) is expressed in most ovarian cancer subtypes and is a novel...

Descripción completa

Detalles Bibliográficos
Autores principales: Estupina, Pauline, Fontayne, Alexandre, Barret, Jean-Marc, Kersual, Nathalie, Dubreuil, Olivier, Le Blay, Marion, Pichard, Alexandre, Jarlier, Marta, Pugnière, Martine, Chauvin, Maëva, Chardès, Thierry, Pouget, Jean-Pierre, Deshayes, Emmanuel, Rossignol, Alexis, Abache, Toufik, de Romeuf, Christophe, Terrier, Aurélie, Verhaeghe, Lucie, Gaucher, Christine, Prost, Jean-François, Pèlegrin, André, Navarro-Teulon, Isabelle
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5513714/
https://www.ncbi.nlm.nih.gov/pubmed/28427157
http://dx.doi.org/10.18632/oncotarget.15715

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5513714/
https://www.ncbi.nlm.nih.gov/pubmed/28427157
http://dx.doi.org/10.18632/oncotarget.15715

Ejemplares similares